Want to see what we’re working on?
Stay in the loop
For the latest updates as they happen, follow us on LinkedIn.
Announcing the launch of our pCPA Temporary Access Process (pTAP)
Following consultations with stakeholders in the late summer and early fall of 2023, we have finalized the principles and conditions for pTAP.
Market exit updates for generic drugs
As of May 1, 2024, changes to the market exit process for generic drugs are in effect.
pTAP consultations: What we heard
In August 2023, the pCPA engaged with clinicians, patient groups and industry to present and hear feedback on a set of principles and conditions for pTAP.
The pCPA Inaugural Report, Marking a Year of Transformation
The pCPA Board of Directors is thrilled to release the organization’s inaugural report.
Notice of the Annual General Meeting 2023
Notice is hereby given that the first Annual General Meeting of the members of the pCPA will take place on October 25, 2023.
New pricing initiative for generic drugs
A new three-year pricing initiative for generic drugs will come into effect on October 1, 2023.
The pCPA Announces Its First CEO
The pCPA Board of Directors is excited to announce that Douglas Clark will become the first CEO of the newly incorporated organization.
Transition to a stand-alone organization now complete
The pan-Canadian Pharmaceutical Alliance is pleased to announce that our transition to a stand-alone organization is now complete.
pCPA transition update — June 2023
The pCPA continues the transition to a stand-alone organization with the expectation that this process will be completed in the summer.
pCPA transition update — April 2023
The pCPA is continuing the transition to a stand-alone organization including recruiting key leaders, ensuring all necessary operational supports are in place